Opendata, web and dolomites

TREAT-PD SIGNED

Patient-specific treatment for Parkinson's disease using reprogrammed skin cells

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TREAT-PD project word cloud

Explore the words cloud of the TREAT-PD project. It provides you a very rough idea of what is the project "TREAT-PD" about.

genes    vitro    efficacy    serve    uncontrolled    transplantation    primary    stem    therapeutic    possibilities    subjected    autologous    remarkable    single    intermediate    extensively    involve    guide    generation    integrates    discovery    types    diseases    simply    parkinson    matched    neurodegenerative    individuals    fetal    dopamine    human    producing    pathology    age    allogeneic    models    cell    da    generate    tools    drug    disease    fibroblasts    donors    reprogramming    vivo    therapy    turned    sequencing    valuable    pluripotent    opens    animal    demand    risk    patient    proliferation    neurons    treating    decisions    diagnostics    tumor    technique    identity    overexpression    emerges    techniques    somatic    screens    direct    validated    converts    assessments    proliferating    hesc    lines    biomedical    functional    potency    healthy    mechanistic    authentic    arise    prove    pd    clinical    vs    cells    minimized    replacement    regarding    subtype    fate    conversion    midbrain    criteria    cellular    combinations   

Project "TREAT-PD" data sheet

The following table provides information about the project.

Coordinator
LUNDS UNIVERSITET 

Organization address
address: Paradisgatan 5c
city: LUND
postcode: 22100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 2˙000˙000 €
 EC max contribution 2˙000˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-COG
 Funding Scheme ERC-COG
 Starting year 2018
 Duration (year-month-day) from 2018-11-01   to  2023-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LUNDS UNIVERSITET SE (LUND) coordinator 2˙000˙000.00

Map

 Project objective

Cellular reprogramming is a new and rapidly emerging field where somatic cells can be turned into pluripotent stem cells or other somatic cell types simply by overexpression of specific combinations of genes. This remarkable discovery allows for the generation of patient specific cell lines that will serve as major tools for understanding how diseases arise and develop, and they may also prove useful for drug screens, diagnostics and other biomedical applications. We have developed a reprogramming technique that directly converts human fibroblasts to functional dopamine (DA) neurons, which is the subtype that is affected in Parkinson’s Disease (PD). This opens up for possibilities to generate therapeutic neurons, including patient specific neurons on demand. These neurons, and the techniques for producing them, will become valuable tools for understanding and treating neurodegenerative diseases such as PD. Direct cell conversion is of particular interest for cell replacement therapy as the reprogramming does not involve a proliferating cell intermediate, and thus the risk of uncontrolled proliferation and tumor formation after transplantation is minimized. This project integrates mechanistic studies based on single cell sequencing to improve the technology and control of cell fate such that a large number of authentic DA neurons are obtained. Induced DA neurons will be generated from individuals with PD and age matched healthy donors and subjected to comparative assessments in vitro and in vivo in order to investigate whether any potential PD-associated pathology emerges in the patient derived cells. This will then guide future decisions regarding autologous vs. allogeneic donors. The cells will be extensively validated using pre-clinical animal models of PD. The studies will include direct comparison with primary fetal and hESC-derived DA neurons on criteria important for clinical use such as midbrain subtype identity and in vivo potency and efficacy.

 Publications

year authors and title journal last update
List of publications.
2018 Claire Henchcliffe, Malin Parmar
Repairing the Brain: Cell Replacement Using Stem Cell-Based Technologies
published pages: S131-S137, ISSN: 1877-7171, DOI: 10.3233/jpd-181488
Journal of Parkinson\'s Disease 8/s1 2020-02-13
2018 Malin Parmar, Olof Torper, Janelle Drouin‐Ouellet
Cell‐based therapy for Parkinson\'s disease: A journey through decades toward the light side of the Force
published pages: 463-471, ISSN: 0953-816X, DOI: 10.1111/ejn.14109
European Journal of Neuroscience 49/4 2020-02-13

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TREAT-PD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TREAT-PD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

CohoSing (2019)

Cohomology and Singularities

Read More  

ChaperoneRegulome (2020)

ChaperoneRegulome: Understanding cell-type-specificity of chaperone regulation

Read More  

SWIP (2019)

Extended short-wave infrared pulsed fibre laser

Read More